ivWatch, a medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, announced the lease signing as the anchor organization of Newport News Tech Center Research Parks Building One. The company is relocating from its Hampton headquarters and Williamsburg research & development (R&D) facility, combining all departments under one roof.

The move signifies our ongoing investment in the region and aligns our strong history of medical innovation with this budding business and entrepreneurial community, said Gary Warren, president and CEO of ivWatch. The Research Park is the type of space we need to expand our clinical and R&D efforts, execute manufacturing and national and international distribution of our product, all while maintaining essential business functions like operations, sales and marketing.

As the anchor tenant occupying more than 25,500 sq. ft., the building will include exterior ivWatch signage. The first-floor manufacturing space will be housed within sleek glass walls, and state-of-the-art R&D and office space will be located on the third floor.

The ivWatch move-in is slated to be complete by mid-2019, and a ribbon-cutting for Building One is planned for August 2019.

To learn more about ivWatch, visit www.ivWatch.com. To learn more about Tech Center Research Park, visit innovateattechcenterva.com.

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

About ivWatch:

ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

Amara Betoney
[email protected]
Direct
(757) 224-2606
Office (855) 489-2824 x7007
Mobile (757)
660-4949





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here